HOME >> MEDICINE >> NEWS
Promising treatments for Huntington's disease identified in UCI study

Irvine, Calif., Feb. 14, 2005 -- UC Irvine researchers have identified several promising drug compounds that when combined show the potential to treat Huntington's disease.

In tests on fruit flies, Larry Marsh and Leslie Thompson found that combinatorial drug therapies developed from these compounds halted the brain-cell damage caused by the fatal, progressive neurodegenerative disorder. Such types of therapies have proven very effective in the treatment of other complex human diseases, like cancers and AIDS. And while any human benefits from this study are years off, the research provides the first evidence that a regimen of complementary drugs can treat Huntington's. Study results appear this week in the early online edition of the Proceedings of the National Academy of Sciences.

"Preclinical testing strategies such as those we used with fruit flies can result in a great savings of cost and time in developing potential disease treatments," Marsh said. "They can serve to rapidly identify treatment regimens that are very likely to provide effective therapeutic benefit to patients."

In developing these drug combinations, Marsh and Thompson chose compounds that individually have been shown in other fruit-fly tests and in mouse models to suppress neurodegeneration, but each targets different cellular processes. Included in these combinations are HDAC inhibitors, which also are showing great promise in cancer-treatment clinical trials. When combined, these compounds showed increased suppression qualities with no toxic side effects.

"That's what's important to note," Marsh said. "Every drug is also a potential poison. Thus, we sought to find several drugs, each of which impacts a different point in the disease process, so that we could use low doses of each single drug, but together their combined effects all converge on a single disease process. This minimizes toxic side effects while maximizing benefit."

Since Huntington's is a
'"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
14-Feb-2005


Page: 1 2 3

Related medicine news :

1. Promising new strategy for Swedish medical research
2. Promising results for malaria vaccine trial
3. Promising diagnostic test for sleeping sickness
4. Promising new treatment options for people with co-existing alcohol-use and psychiatric disorders
5. Promising drug fails to thwart fatal lung disease in large trial
6. Promising drug proves ineffective as treatment for hearing loss
7. Promising West Nile virus vaccine protects monkeys
8. Promising new treatment preserves bone mass in mice; May help women and men with osteoporosis
9. Promising vaccine may provide long-lasting protection against malaria
10. Promising new research on schizophrenia causes
11. UI Study Suggests Promising Treatment For Diabetic Pregnancies

Post Your Comments:
(Date:6/29/2015)... CA (PRWEB) , ... June 29, 2015 , ... ... and imprinted accessories, is offering discounted pricing on all purchases that include branding. ... foundation of a brand is the logo. The website, packaging and promotional materials, all ...
(Date:6/29/2015)... VA (PRWEB) , ... June 29, 2015 , ... ... services to government contractors, nonprofits, independent schools, and other growing businesses across the ... Insights Top 100 Value Added Resellers for the fifth consecutive year. , Based ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors and Usability Studies: ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors , The ... to the design of new products as well as to postmarket surveillance of ...
(Date:6/29/2015)... , ... June 29, 2015 , ... People across the country give their coworkers and ... part of our culture. , But, how often do coworkers donate “life” to the ... a simple one. , “Dawna (Wright-Thompson) told me her husband was on a ...
(Date:6/29/2015)... ... June 29, 2015 , ... Two ... against C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in New ... Management Conference is to be convened on Thursday, July 23rd at 12:00 p.m. ...
Breaking Medicine News(10 mins):Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4
(Date:6/29/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... is now included in the Russell 3000®, the Russell ... to the indexes occurred at the close of trading ... its comprehensive set of U.S. and global indexes. ... Cap and Global Indexes coincides with the progress we ...
(Date:6/29/2015)... , June 29, 2015  Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced ... study with novel formulations of oral, enteric-coated buprenorphine ... chronic pain and opioid dependence indications has reached ... company anticipates reporting top-line results in the second ...
(Date:6/29/2015)... England , June 29, 2015  Eli ... Immunocore Limited today announced that they have entered ... the utility of Immunocore,s lead T cell receptor-based ... (LY2157299) and merestinib (LY2801653) for the treatment of ... identify combination regimens that provide synergies in efficacy ...
Breaking Medicine Technology:Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 2Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 3Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 2Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 2Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 4Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 5Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 6Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 7
Cached News: